Amundi Grows Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Amundi raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 4,303 shares of the company’s stock after purchasing an additional 65 shares during the quarter. Amundi’s holdings in Medpace were worth $1,526,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of MEDP. R Squared Ltd purchased a new stake in shares of Medpace during the fourth quarter worth $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of Medpace during the fourth quarter worth $31,000. Stone House Investment Management LLC purchased a new stake in shares of Medpace in the third quarter valued at about $33,000. Jones Financial Companies Lllp grew its holdings in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after purchasing an additional 110 shares during the period. Finally, Lindbrook Capital LLC grew its holdings in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP stock opened at $326.34 on Tuesday. The firm has a market cap of $9.94 billion, a PE ratio of 25.84, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The company has a 50-day moving average of $339.97 and a two-hundred day moving average of $340.56. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Medpace has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.